Dose-finding Study of LFB-R593, A Monoclonal Anti-RhD Antibody, in Healthy RhD Negative Volunteers
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This phase II study is designed to demonstrate the ability of LFB-R593 to effectively
eliminate exogenously-administered RhD-positive red blood cells from the circulation of an
RhD-negative individual, thereby preventing RhD-alloimmunisation.
Phase:
Phase 2
Details
Lead Sponsor:
Laboratoire français de Fractionnement et de Biotechnologies